drugset / Trial / NCT00209690
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
Phase 1/2
Completed
30 enrolled
Hokkaido Gastrointestinal Cancer Study Group
Hokkaido University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in untreated patients with metastatic esophageal cancer. The usefulness of the this regimen is evaluated by response rate, median survival time, and progression free survival.
Timeline
- Start
- 2003-10
- Primary completion
- 2009-12
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 15 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | fluorouracil | Small molecule | 800 mg/m2 | Intravenous |